It lessens viral load and disease severity by preventing the virus from spreading. The first oral antiviral drug, Molnunat, aids in the treatment of adults with mild to moderate COVID-19. On December 28, 2021, the drug received approval from Indian drug regulatory authorities for use in emergencies.
Similar Products:
Molnupiravir, Chloroquine, Baricitinib, Zithromax, Azithromycin, Barikind, Barilup, Ivermectin, Plaquenil
FDA and the UK's regulatory body for emergency use. When a patient needs to be hospitalized right away because of COVID-19, it is not advised. Patients with mild to moderate COVID-19 symptoms who are at a high risk of progressing to severe symptoms should only take molnunat, according to the recommended dosage. Obesity, advanced age (>60 years), type 2 diabetes, and cardiovascular disease are risk factors. The United States has also approved this medication.
Discuss any such side effects with the doctor if you experience any. Do not stop taking the medication even if you feel better because it is crucial to complete the entire 5-day course of treatment. Molnunat shouldn't be taken orally for more than five days in a row. In some patients, the medication may result in nausea, vomiting, diarrhea, and dizziness. They might offer suggestions for prevention measures or assistance with the treatment.
The use of Molnunat entails a number of significant risks, including the possibility that it could lead to birth defects in expectant mothers and serious harm to the development of bones and cartilage (which could result in serious muscle damage). As a result, Molnunat should only be taken as directed by a physician and should not be used for self-medication.
| Target Point | Shipping Method | Tracking | Delivery Time | Price |
|---|---|---|---|---|
Worldwide shipping |
|
Not trackable | 14-21 business days | USD 20.00 per order |
|
Trackable, where available | 5-9 business days | USD 30.00 per order |
Delivery time is:
Registered Mail
-
14-21
business days,
prices
-
USD 20.00,
no signature is required on delivery.
EMS
-
5-9
business days,
prices
-
USD 30.00,
signature is required on delivery.
Your order will be packed safe and secure and dispatched within 24 hours.
 |
 |
 |
This is exactly how your parcel will look like (pictures of a real shipping item). It has a look of a regular private letter and does not disclose its contents. Size - 9.4x4.3x0.3 inches (24x11x0.7cm).
Awards and Certificates (Сlick to view the certificate verification)
Molnunat 200™ (molnupiravir) is a licensed generic of Lagevrio® produced in an FDA approved manufacturing facility in India. It should be given to patients at high risk of hospitalization or death when other authorized treatments are inaccessible or clinically inappropriate. Molnupiravir received emergency use authorization from the USFDA and the UK drugs regulator for the treatment of COVID-19.